Comparative Pharmacology
Head-to-head clinical analysis: LOZOL versus MYKROX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOZOL versus MYKROX.
LOZOL vs MYKROX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron, reducing plasma volume and extracellular fluid volume; also causes direct vasodilation through modulation of calcium channels.
MYKROX (metolazone) is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule by blocking the Na+-Cl- cotransporter, leading to increased excretion of sodium, chloride, and water.
Indapamide: Oral, 1.25 mg once daily. May increase to 2.5 mg once daily if no response after 4 weeks.
Adults: 1 mg orally once daily, preferably in the morning.
None Documented
None Documented
Terminal half-life: 14-18 hours (mean 16 hours); clinically significant for once-daily dosing
Terminal elimination half-life: 50–70 hours; achieves steady-state after ~2 weeks of once-daily dosing; prolonged in hepatic impairment but not significantly altered in renal impairment.
Renal: 70% unchanged, Biliary/Fecal: 30% as metabolites
Primarily hepatic metabolism (CYP3A4) to inactive metabolites; renal excretion accounts for <10% as unchanged drug; biliary/fecal excretion of metabolites ~75%.
Category C
Category C
Thiazide-like Diuretic
Thiazide-like Diuretic